Results 11 to 20 of about 178,847 (197)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

PLoS ONE, 2020
Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells.
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Erina Minato, Atsushi Kobayashi, Ryo Ando, Nobuya Sasaki, Daisuke Miyakoshi, Osamu Ichii, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +14 more
doaj   +1 more source

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

Cancer Medicine, 2020
Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains ...
Yuka Suzuki, Kei Kohno, Kosei Matsue, Ayako Sakakibara, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Seiyo Mabuchi, Taishi Takahara, Seiichi Kato, Shigeo Nakamura, Akira Satou   +11 more
doaj   +1 more source

Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor

Bio-Protocol, 2023
Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo, huifang Li, Justin Gutkowski, Ang Cai, Navindra Seeram, Hang Ma, Chang Liu   +6 more
doaj   +1 more source

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

Journal of Translational Medicine, 2020
Background Previous studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist.
Karolina Okła, Alicja Rajtak, Arkadiusz Czerwonka, Marcin Bobiński, Anna Wawruszak, Rafał Tarkowski, Wiesława Bednarek, Justyna Szumiło, Jan Kotarski   +8 more
doaj   +1 more source

Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells

Cell Communication and Signaling, 2023
Background PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC).
Anudari Letian, Eyoel Yemanaberhan Lemma, Paola Cavaliere, Noah Dephoure, Nasser K. Altorki, Timothy E. McGraw   +5 more
doaj   +1 more source

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Cell Death and Disease, 2022
Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee, So Young Kim, Songhee H. Kim, Seoyeon Choi, Bin Lee, Jeon-Soo Shin   +5 more
doaj   +1 more source

Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer

Cancer Nanotechnology, 2023
Blocking the binding of PD-1/PD-L1 has become an effective strategy in inhibition of tumor immune escape. At present, it mainly depends on the employment of macromolecular antibodies, which target PD-1/PD-L1 protein through binding one of PD-1 or PD-L1 ...
Wenwen Ji, Bei Zhang, Xuetong Sun, Lijuan Ma, Xiangying Zhang, Wenhui Qian, Wenjuan Fu, Jianting Li, Dong Zhu   +8 more
doaj   +1 more source

PD-L1: expression regulation

Blood Science, 2023
Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their ...
Yu-Jie Zhou, Guoli Li, Jiyin Wang, Mengyuan Liu, Zihan Wang, Yu Song, Xulong Zhang, Xi Wang   +7 more
doaj   +1 more source

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

JCI Insight, 2022
Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine.
Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama   +18 more
doaj   +1 more source